Steelers defensive end Yahya Black is putting AAMDSIF in the spotlight—add your support with a gift today.
Abstract NRAS and KRAS mutations, commonly identified alongside ancestral co-mutations, are generally regarded as pathogenic in adults presenting with monocytosis and/or cytopenia(s). However, their significance in isolation is not well defined. We studied a multi-institutional…
Abstract Improved ex vivo expansion of human haematopoietic stem cells (HSCs) would considerably advance transplantation and genome-engineered therapies, yet existing culture methods still allow substantial HSC loss. Here we show that this attrition is driven largely by…
This 30-minute webinar reviews the range of opportunities for health care providers to incorporate quality of life considerations with bone marrow failure patients and their caregivers. Assessing resources needed for patients and communicating with the entire health care team…
This informative 30-minute webinar provides practical recommendations for how health care providers can coordinate care for their bone marrow failure patients. Communication among members of the entire health care team managing these patients will also be discussed. This webinar…
Dr. Patel discusses how health care providers, especially those in community settings, can connect patients with aplastic anemia, MDS, or PNH with AAMDSIF patient education resources and support. View, download, or order AAMDSIF patient guides and fact sheets here: https://www…
Aged individuals with somatic TP53 mutations manifest clonal hematopoiesis (CH) and are at high risk of developing myeloid neoplasms. However, the underlying mechanisms are not fully understood. Here we show that inflammatory stress confers a competitive advantage to p53 mutant…
Abstract NRAS and KRAS mutations, commonly identified alongside ancestral co-mutations, are generally regarded as pathogenic in adults presenting with monocytosis and/or cytopenia(s). However, their significance in isolation is not well defined. We studied a multi-institutional…
NIH clinical trial shows promise for people with treatment-limited, life-threatening disorder. A clinical trial at the National Institutes of Health (NIH) has shown that an experimental treatment for patients with severe aplastic anemia resulted in a 94% survival rate without…
Key Takeaways The combination therapy achieved a 91% overall response rate, with 45% complete remission and 46% marrow complete remission rates. Median overall survival was 30 months, with 1- and 3-year survival rates of 68.8% and 40.7%, respectively. SHOW MORE Decitabine…
